

The incidence of increased BMI and metabolic syndrome in causing benign prostatic hyperplasia in young, obese males (under 40 years)

Abstract

Background: Benign prostatic hyperplasia is a prevalent condition affecting men, with risk factors such as age, lifestyle, inflammation, sex hormones, and genetics. However, the link between metabolic syndrome and BPH has gained attention, particularly among young, obese males under 40.

Literature Review: This review explores the incidence and impact of increased body mass index and metabolic syndrome in causing benign prostatic hyperplasia (BPH) in young, obese males, particularly those under 40 years old. The connection between BPH and MetS was first noted over twenty years ago by Hammarsten and colleagues, who found a direct correlation between Mets components and prostate volume. Subsequent studies in the United States and the United Kingdom corroborated these findings, showing that young males with three or more MetS components have a higher risk of developing BPH. Studies employing the American Urological Association Symptom Index indicated that men with mild lower urinary tract symptoms (LUTS) significantly increased MetS prevalence among men under 40 years old. Research in Asia has highlighted a growing incidence of LUTS, correlating with increased blood pressure, fasting blood glucose, and increased BMI. A meta-analysis found a 28% higher chance of developing BPH among men with higher BMI, and Obese persons were found to have a chance of having an enlarged prostate that was three and a half times higher than the average. Besides BMI, Various studies have examined other clinical markers associated with obesity, such as dyslipidemia and elevated serum insulin levels, which have been linked to increased prostate growth rates.

Conclusion: These findings underscore the need for further research to understand the mechanisms and address the disparities in BPH prevalence among different racial and ethnic groups. Addressing obesity and MetS through lifestyle modifications and medical interventions could potentially reduce BPH incidence in young, obese males.

Keywords: Benign Prostate Hyperplasia, Metabolic Syndrome, Body Mass Index, BMI

Introduction

Benign prostatic hyperplasia is a prevalent and distressing condition that affects men(1). It is estimated that approximately 25 percent of men under the age of 40 and approximately 70 percent of men over the age of 70 have BPH(2). Five general categories of risk factors for BPH exist at the population level. Other categories include inflammation, modifiable lifestyle factors, sex steroid hormones and genetics in addition to age(3). However, neither of these risk factors has yet been agreed upon as a definitive cause of BPH incidence or progression(3).

Metabolic syndrome is a complex illness that poses a significant socioeconomic burden and is widely recognized as a global epidemic(4). MetS is characterized by a combination of factors that greatly increase the likelihood of developing coronary heart disease(4). The main features of this condition include dysregulated glucose homeostasis, elevated blood pressure, and dyslipidemia(4). However, abdominal obesity and insulin resistance have emerged as key manifestations of the syndrome.

Studies on BPH often overlook ethnic/racial prevalence. However, research has shown that men under 40 from minority groups, such as African Americans and Hispanics, face a higher risk of developing BPH(5). In addition, numerous studies have examined the impact of metabolic syndrome and obesity on BPH, specifically looking at factors such as hyperlipidemia, waist circumference, obesity, high blood sugar, and hypertension. According to this study, it has been found that metabolic diseases, increased BMI, and obesity are potential risk factors for BPH(6, 7). Although increased BMI is common among African Americans and Hispanics(8), there is still much to learn about the connection between increased BMI and BPH in these communities and the reasons behind the disparities.

There is a hypothesis that suggests that obesity can potentially trigger the development of BPH. This hypothesis proposes that pro-inflammatory states caused by obesity can lead to reactive changes in the stromal and epithelial microenvironment(9). These changes can be observed through alterations in the expression of genes related to inflammatory response, as well as cell development and growth (9). However, the impact of metabolic diseases and obesity on BPH molecular and pathologic profiles remains uncertain, particularly in medically underserved populations such as HAs(9).

The purpose of this review is to explore the incidence of increased BMI and metabolic syndrome in causing benign prostatic hyperplasia in young, obese males, especially those who are under 40 years old.

Epidemiology of MetS in men under 40 with BPH

The first time that researchers noticed a connection between BPH and metabolic syndrome (MetS) was over twenty years ago(1). In a study that was considered to be groundbreaking, Hammarsten and colleagues found that there is a direct connection between the volume of the prostate and the various components of Metabolic Syndrome in men who have BPH(10). In the United States, a comprehensive investigation was conducted on the population, with a particular emphasis on 2372 male participants(11). This study sheds light on the connection between metabolic illnesses and the development of BPH. The findings of the study indicate that males below 40 years of age who have three or more components of the Mets are at a greater risk of developing BPH. The presence of a history of hypertension, low-density lipoprotein, and high-density lipoprotein were all found to be associated with substantial positive correlations.

In a study, males ranging in age from 18 to 50 years were included as participants(12). Using the American Urological Association Symptom Index, the researchers rated the symptoms that they were experiencing in their lower urinary tract. The index was divided into three categories: none (0-1), mild (2-7), and moderate or severe (8-35). Revised NCEP-ATP III standards were utilized to define the Mets. A substantial rise of approximately forty percent in the prevalence of MetS was observed in those who had mild LUTS. On the other hand, the group that had moderate to severe LUTS did not show any further signs of increasing. The significance of these relationships

was found to be more pronounced in males who were younger than fifty years old. According to the findings of a study that was carried out in the United Kingdom, it was shown that a large number of men who had BPH also had MetS, with a prevalence rate consisting of 26.5%(13). When compared to men who do not have clinical BPH, those who do have clinical BPH do have a 37% higher risk of acquiring metabolic syndrome.

In the coming years, it is projected that the incidence of LUTS will increase all across the world, especially in Asia(14). A high incidence rate of 44.8% was observed in Asia in 2008, and this percentage has now climbed to 45.5% in 2018(14). When taking into account the increasing systolic blood pressure, increasing levels of fasting blood glucose, and increasing levels of BMI in Asian men, it is of the utmost importance to acknowledge the considerable impact that this has on the prevalence of metabolic syndrome and the regional burden of the disease in this community.

The incidence of increased BMI and metabolic syndrome in causing benign prostatic hyperplasia in young, obese males under 40 years old

The United States of America is currently facing a major problem with obesity, which is scientifically defined as having a body mass index (BMI) that is greater than 30 (15). The prevalence has been increasing at a rate that is cause for concern, and it is currently affecting 36.8% of persons aged 40 to 59 and 31% of those aged 60 or older(16). The prevalence of obesity in men has seen a significant increase in recent years. From 1999 to 2000, it stood at 27.5%, but from 2003 to 2004, it had risen to 31.1%(15). According to the statistics it was shown that there were no variations in the prevalence of individuals with an increased body mass index (BMI) or obesity among males of different racial backgrounds(16).

As the number of people struggling with obesity continues to rise in the United States, so does the prevalence of obesity-related disorders like dyslipidemia, hypertension, and blood pressure(17). Men frequently receive a diagnosis of metabolic syndrome according to the Adult Treatment Panel III (ATPIII) criteria. This includes having three or more of the following: “blood pressure that is higher than 135/85, a waist circumference that is greater than 102 centimeters, triglyceride levels that are higher than 1.7 mmol/L, low levels of high-density lipoprotein (HDL)

that are below 1.0 mmol/L, and fasting plasma glucose levels that are higher than 6.1 mmol/L(18).

BPH is also highly influenced by another metabolic syndrome component, increased central adiposity, as measured by waist circumference (19). Older and obese patients had significantly greater disparities in total prostate volume, according to a 2015 meta-regression study of eight studies (n = 5403)(19). Even if WC, a central obesity index, was added as an additional covariate along with age and PSA level, it continued to be an independent predictor in the relationship between the increase in prostatic volume in the transitional zone and overall(19). This is consistent with a prior meta-analysis, which found that obesity, as determined by BMI, was associated with a 28% higher chance of developing BPH(20).

The impact of obesity and illnesses connected to obesity on the development of LUTS and BPH has been the subject of a study done by a great number of organizations over the past few years(21). Nevertheless, their research has shown contradictory results. Obesity, particularly in the abdomen region, has been proven to contribute, to varied degrees, to an elevated risk of both LUTS and BPH, according to the findings of a number of research departments and organizations. An investigation on the progression of benign prostatic hyperplasia was carried out, and it lasted from 1961 to 1982(22). With an adjusted odds ratio of 3.52 and a 95% confidence interval ranging from 1.93-6.42, it was discovered that an increased BMI is a significant predictor of a clinical diagnosis of BPH. Adedew et al. (23) conducted a subsequent study in which they studied the relationship between increased BMI and LUTS. According to this research, a BMI of greater than 25 beyond the age of 25 was found to be negatively associated with lower urinary tract syndrome (LUTS), given that the odds ratio is 1.90 and the confidence range extends from 0.89 to 4.05. Also, it was noticed that males who had a waist circumference that was greater than 102 centimeters had a greater risk of developing LUTS in comparison to those who had a waist circumference that was smaller. According to the calculations, the odds ratio was found to be 1.48, and the confidence interval for the 95% range was between 0.87 and 2.54. According to the data, a higher risk of symptoms related to the lower urinary system may be associated with increasing weight and collecting fat around the abdomen in adulthood. On the other hand, it is possible that these findings do not apply to everyone. In a study that was carried out by Joseph et al. (24), the modifiable risk factors for LUTS in black

men were investigated. They took a sample of 708 men under 40 years old and found that there was no correlation between having a higher body mass index and an increased incidence of lower urinary tract syndrome (LUTS).

Prostate volume increased by 0.41 mL for every kg/m² rise in BMI in the Baltimore Longitudinal Study of Ageing. Compared to non-obese individuals, obese persons had a three-and-a-half times greater likelihood of having an enlarged prostate(25). Additionally, rather than focusing just on BMI, some researchers and physicians have investigated a wider range of clinical markers associated with obesity(26). To this goal, Hammarsten and colleagues (27) used ultrasound to monitor the growth rates of the prostate in 307 men under 40 who were diagnosed with LUTS. Greater annual prostate growth rates were shown to be connected with higher fasting plasma levels, dyslipidemia, waist circumference, and elevated BMI. In a case-control study, Dahle et al. (28) compared twenty-two men who were hospitalized for surgery related to benign prostatic hyperplasia to thirty-two healthy men who were chosen at random. They found that a significant association existed between an increased risk of abdominal obesity and BPH, as well as elevated serum insulin levels. In their study, both the cases and the controls had a BMI that was significantly lower than the definitions of obesity in the United States, with an average BMI of roughly 22.

Conclusion

The review underscores the significant role that increased BMI and metabolic syndrome (MetS) play in the development of benign prostatic hyperplasia (BPH) among young, obese males, particularly those under 40 years old. Evidence from various studies reveals a direct correlation between increased BMI, MetS components, and the risk of BPH, highlighting the influence of central adiposity and related metabolic disturbances. While BMI is a well-established risk factor, the impact of other MetS components, such as dyslipidemia and insulin resistance, also emerges as crucial in understanding the pathophysiology of BPH. Despite some inconsistencies in research findings, the overall trend suggests that addressing higher BMI and MetS could potentially mitigate the incidence of BPH. Future research should focus on elucidating the underlying mechanisms and exploring the disparities in BPH prevalence across different racial and ethnic groups. Implementing lifestyle modifications and medical interventions targeting

higher BMI and MetS may prove beneficial in reducing the burden of BPH in this demographic, thereby improving men's health outcomes.

References

1. Ngai HY, Yuen KS, Ng CM, Cheng CH, Chu SP. Metabolic syndrome and benign prostatic hyperplasia: An update. *Asian J Urol.* 2017;4(3):164-73.
2. Kaplan SA, Lee JY, Meehan AG, Kusek JW. Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: the MTOPS trial. *The journal of urology.* 2016;195(6):1825-9.
3. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. *Indian Journal of Urology.* 2014;30(2):170-6.
4. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. *BMC medicine.* 2011;9:1-13.
5. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. *Urologic Clinics.* 2016;43(3):289-97.
6. Meng J, Liu Y, Guan S-Y, Ma H, Zhang X, Fan S, et al. Age, height, BMI and FBG predict prostate volume in aging benign prostatic hyperplasia: Evidence from 5285 patients. *International Journal of Clinical Practice.* 2019;73(12):e13438.
7. Li B-H, Deng T, Huang Q, Zi H, Weng H, Zeng X-T. Body mass index and risk of prostate volume, international prostate symptom score, maximum urinary flow rate, and post-void residual in benign prostatic hyperplasia patients. *American Journal of Men's Health.* 2019;13(4):1557988319870382.
8. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States. *NCHS data brief.* 2020;360:1-8.
9. Fowke JH, Koyama T, Fadare O, Clark PE. Does inflammation mediate the obesity and BPH relationship? An epidemiologic analysis of body composition and inflammatory markers in blood, urine, and prostate tissue, and the relationship with prostate enlargement and lower urinary tract symptoms. *PloS one.* 2016;11(6):e0156918.
10. Li J, Peng L, Cao D, Gou H, Li Y, Wei Q. The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis. *The Aging Male.* 2020;23(5):1388-99.
11. Wu S, He H, Wang Y, Xu R, Zhu B, Zhao X. Association between benign prostate hyperplasia and metabolic syndrome in men under 60 years old: a meta-analysis. *Journal of International Medical Research.* 2019;47(11):5389-99.
12. Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. *The Journal of urology.* 2009;182(2):616-25.
13. DiBello JR, Ioannou C, Rees J, Challacombe B, Maskell J, Choudhury N, et al. Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study. *BJU international.* 2016;117(5):801-8.
14. Attia AAM, AbdElaal HM, Yasien HA, Elgharbawy MS. Correlation between metabolic syndrome and benign prostatic hyperplasia. *Menoufia Medical Journal.* 2021;34(1):43-6.
15. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. *Jama.* 2006;295(13):1549-55.
16. Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Current Prostate Reports.* 2006;4(3):127-31.

17. Yoo S, Oh S, Park J, Cho SY, Cho MC, Jeong H, et al. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men. *BJU International*. 2019;123(1):140-8.
18. Lemieux I, Després J-P. Metabolic syndrome: past, present and future. *MDPI*; 2020. p. 3501.
19. Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. *BJU international*. 2015;115(1):24-31.
20. Wang S, Mao Q, Lin Y, Wu J, Wang X, Zheng X, et al. Body mass index and risk of BPH: a meta-analysis. *Prostate cancer and prostatic diseases*. 2012;15(3):265-72.
21. Batai K, Phung M, Bell R, Lwin A, Hynes KA, Price E, et al. Correlation between body mass index and prostate volume in benign prostatic hyperplasia patients undergoing holmium enucleation of the prostate surgery. *BMC urology*. 2021;21(1):88.
22. Khan S, Wolin K, Pakpahan R, Grubb R, Colditz G, Ragard L, et al. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia. *BMC urology*. 2021;21:1-13.
23. Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Healthy Longevity*. 2022;3(11):e754-e76.
24. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. *American Journal of Epidemiology*. 2003;157(10):906-14.
25. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. *The Journal of Clinical Endocrinology & Metabolism*. 2006;91(7):2562-8.
26. Chen W, Man S, Wang B, Kadeerhan G, Huang X. Metabolically healthy obesity is associated with increased risk of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A cohort study of Chinese elderly males. *LUTS: Lower Urinary Tract Symptoms*. 2022;14(3):170-7.
27. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. *European urology*. 2001;39(2):151-8.
28. Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. *The Journal of urology*. 2002;168(2):599-604.